Role of nanotechnology in targeted drug delivery and imaging: a concise review

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 1, Issue 3, 2005, Pages 193-212

  Koo, Otilia M ^a   Rubinstein, Israel ^a,b,c   Onyuksel, Hayat ^a,d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

^d University of Illinois at Chicago   (United States)

Author keywords

Imaging; Nanotechnology; Systemic administration; Targeted drug delivery

Indexed keywords

LIPOSOMES; SYSTEMIC ADMINISTRATION; TARGETED DRUG DELIVERY; VASCULAR LEAKINESS;

CELLS; DENDRIMERS; DRUG THERAPY; EMULSIONS; MEDICAL IMAGING; TISSUE; TOXICITY;

NANOTECHNOLOGY;

2 DEVINYL 2 (1 HEXYLOXYETHYL)PYROPHEOPHORBIDE; ALBUMIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTINEOPLASTIC AGENT; BENZATHINE PENICILLIN; CAMPTOTHECIN; CONTRAST MEDIUM; CREMOPHOR; CYCLOSPORIN A; DAUNORUBICIN; DENDRIMER; DEXAMETHASONE; DIAZEPAM; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; INDOMETACIN; LIPID; LIPOSOME; NANOCRYSTAL; NK 911; OLIGONUCLEOTIDE; PACLITAXEL; PHOSPHOLIPID; POLOXAMER; POLYESTER; POLYMER; QUANTUM DOT; RADIOPHARMACEUTICAL AGENT; SP 1049 C; TAMOXIFEN; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINYL DERIVATIVE;

BIOLOGY; BIOPHYSICS; BLOOD VESSEL PERMEABILITY; CANCER CELL; CANCER RESISTANCE; CANCER TISSUE; CELL; CELL TRANSPORT; CERAMICS; CLINICAL TRIAL; COMPOSITE MATERIAL; COST; DISEASE MODEL; DRUG COST; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; EMULSION; EXPERIMENTAL MODEL; FLUORESCENCE; GEL; GENE OVEREXPRESSION; HUMAN; IMAGING; IN VIVO STUDY; INFLAMMATION; INJURY; LARGE SCALE PRODUCTION; MAGNETISM; METHODOLOGY; MICELLE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PARTICULATE MATTER; PERIPHERAL NEUROPATHY; PHAGOCYTE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID; TISSUE; TOXICITY;

ANIMALS; DIAGNOSTIC IMAGING; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NANOTECHNOLOGY; PHAGOCYTES;

ANIMALIA;

EID: 33745513833     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2005.06.004     Document Type: Review

References (212)

1. National Science and Technology Council Committee on Technology. The National Nanotechnology Initiative: research and development leading to a revolution in technology and industry (2005), Office of Science and Technology Policy, Washington (DC)
2. Brayden D.J. Controlled release technologies for drug delivery. Drug Discov Today 8 (2003) 976-978
3. Hughes G.A. Nanostructure-mediated drug delivery. Nanomedicine 1 (2005) 22-30
4. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51 (1999) 691-743
5. Au J.L., Jang S.H., Zheng J., Chen C.T., Song S., Hu L., et al. Determinants of drug delivery and transport to solid tumors. J Control Release 74 (2001) 31-46
6. Fetterly G.J., and Straubinger R.M. Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS Pharm Sci 5 (2003) E32
7. Hoarau D., Delmas P., David S., Roux E., and Leroux J.C. Novel long-circulating lipid nanocapsules. Pharm Res 21 (2004) 1783-1789
8. Moghimi S.M., and Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42 (2003) 463-478
9. Koo O., Rubinstein I., and Onyuksel H. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine 1 (2005) 77-84
10. Kristl J., Volk B., Gasperlin M., Sentjurc M., and Jurkovic P. Effect of colloidal carriers on ascorbyl palmitate stability. Eur J Pharm Sci 19 (2003) 181-189
11. Arnedo A., Irache J.M., Merodio M., Espuelas M., and Millan S. Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. J Control Release 94 (2004) 217-227
12. Sethi V., Onyuksel H., and Rubinstein I. Enhanced circulation half-life and reduced clearance of vasoactive intestinal peptide (VIP) loaded in sterically stabilized micelles (SSM) in mice with collagen-induced arthritis (CIA). AAPS PharmSci 5 (2003) M1045
13. Zhang J.A., Anyarambhatla G., Ma L., Ugwu S., Xuan T., Sardone T., et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 59 (2005) 177-187
14. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8 (2002) 1038-1044
15. Kim T.Y., Kim D.W., Chung J.Y., Shin S.G., Kim S.C., Heo D.S., et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10 (2004) 3708-3716
16. Krishnadas A., Rubinstein I., and Onyuksel H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm Res 20 (2003) 297-302
17. Gelderblom H., Verweij J., Nooter K., and Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37 (2001) 1590-1598
18. tenTije A.J., Verweij J., Loos W.J., and Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42 (2003) 665-685
19. Oeffinger B.E., and Wheatley M.A. Development and characterization of a nano-scale contrast agent. Ultrasonics 42 (2004) 343-347
20. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
21. Brown L.F., Detmar M., Claffey K., Nagy J.A., Feng D., Dvorak A.M., et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. In: Goldberd I.D., and Rosen E.M. (Eds). Regulation of angiogenesis (1997), Birkhauser Verlag, Basel 233-269
22. Matsumura Y., Kimura M., Yamamoto T., and Maeda H. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn J Cancer Res 79 (1988) 1327-1334
23. Wu J., Akaike T., and Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res 58 (1998) 159-165
24. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 95 (1998) 4607-4612
25. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. J Control Release 53 (1998) 49-67
26. Fu B.M., Adamson R.H., and Curry F.E. Test of a two-pathway model for small-solute exchange across the capillary wall. Am J Physiol 274 (1998) H2062-H2073
27. Firth J.A. Endothelial barriers: from hypothetical pores to membrane proteins. J Anat 200 (2002) 541-548
28. Meyer D.E., Shin B.C., Kong G.A., Dewhirst M.W., and Chilkoti A. Drug targeting using thermally responsive polymers and local hyperthermia. J Control Release 74 (2001) 213-224
29. Nelson J.L., Roeder B.L., Carmen J.C., Roloff F., and Pitt W.G. Ultrasonically activated chemotherapeutic drug delivery in a rat model. Cancer Res 62 (2002) 7280-7283
30. Tao W.M., and Zhang M. A genetic algorithm-based area coverage approach for controlled drug delivery using microrobots. Nanomedicine 1 (2005) 91-100
31. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53 (2001) 283-318
32. Klibanov A.L., Maruyama K., Torchilin V.P., and Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268 (1990) 235-237
33. Allen T.M., Hansen C., Martin F., Redemann C., and Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066 (1990) 29-36
34. Woodle M.C. Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. Chem Phys Lipids 64 (1993) 249-262
35. Allen T.M., and Everest J.M. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. J Pharmacol Exp Ther 226 (1983) 539-544
36. Ballabh P., Braun A., and Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16 (2004) 1-13
37. Oki T., Takahashi S., Kuwabara S., Yoshiyama Y., Mori M., Hattori T., et al. Increased ability of peripheral blood lymphocytes to degrade laminin in multiple sclerosis. J Neurol Sci 222 (2004) 7-11
38. Inoue S. Basement membrane and beta amyloid fibrillogenesis in Alzheimer's disease. Int Rev Cytol 210 (2001) 121-161
39. Cornford E.M., and Cornford M.E. New systems for delivery of drugs to the brain in neurological disease. Lancet Neurol 1 (2002) 306-315
40. Missailidis S., Thomaidou D., Borbas K.E., and Price M.R. Selection of aptamers with high affinity and high specificity against C595, an anti-MUC1 IgG3 monoclonal antibody, for antibody targeting. J Immunol Methods 296 (2005) 45-62
41. Farokhzad O.C., Jon S., Khademhosseini A., Tran T.N., Lavan D.A., and Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64 (2004) 7668-7672
42. Medina O.P., Kairemo K., Valtanen H., Kangasniemi A., Kaukinen S., Ahonen I., et al. Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide. Anticancer Res 25 (2005) 33-42
43. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63 (2003) 7400-7409
44. Dharap S.S., Qiu B., Williams G.C., Sinko P., Stein S., and Minko T. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release 91 (2003) 61-73
45. Mitra A., Mulholland J., Nan A., McNeill E., Ghandehari H., and Line B.R. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release 102 (2005) 191-201
46. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32 (2004) e149
47. Moody T.W., Leyton J., Gozes I., Lang L., and Eckelman W.C. VIP and breast cancer. Ann N Y Acad Sci 865 (1998) 290-296
48. Li L., Wartchow C.A., Danthi S.N., Shen Z., Dechene N., Pease J., et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys 58 (2004) 1215-1227
49. Fonseca M.J., Jagtenberg J.C., Haisma H.J., and Storm G. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate. Pharm Res 20 (2003) 423-428
50. Gosk S., Vermehren C., Storm G., and Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J Cereb Blood Flow Metab 24 (2004) 1193-1204
51. Ni S., Stephenson S.M., and Lee R.J. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res 22 (2002) 2131-2135
52. Maruyama K., Ishida O., Kasaoka S., Takizawa T., Utoguchi N., Shinohara A., et al. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). J Control Release 98 (2004) 195-207
53. Omori N., Maruyama K., Jin G., Li F., Wang S.J., Hamakawa Y., et al. Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol Res 25 (2003) 275-279
54. Ishida O., Maruyama K., Tanahashi H., Iwatsuru M., Sasaki K., Eriguchi M., et al. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res 18 (2001) 1042-1048
55. Willis M., and Forssen E. Ligand-targeted liposomes. Adv Drug Deliv Rev 29 (1998) 249-271
56. Sapra P., and Allen T.M. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 42 (2003) 439-462
57. Harding J.A., Engbers C.M., Newman M.S., Goldstein N.I., and Zalipsky S. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta 1327 (1997) 181-192
58. Metselaar J.M., Mastrobattista E., and Storm G. Liposomes for intravenous drug targeting: design and applications. Mini Rev Med Chem 2 (2002) 319-329
59. Nobs L., Buchegger F., Gurny R., and Allemann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci 93 (2004) 1980-1992
60. Dagar S., Sekosan M., Lee B.S., Rubinstein I., and Onyuksel H. VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery. J Control Release 74 (2001) 129-134
61. Sethi V., Onyuksel H., and Rubinstein I. A novel therapy for rheumatoid arthritis using a-helix VIP. FASEB 2003 conference proceedings, San Diego, CA (2003) 660
62. Koval M., Preiter K., Adles C., Stahl P.D., and Steinberg T.H. Size of IgG-opsonized particles determines macrophage response during internalization. Exp Cell Res 242 (1998) 265-273
63. Harashima H., Sakata K., Funato K., and Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 11 (1994) 402-406
64. Rejman J., Oberle V., Zuhorn I.S., and Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 377 (2004) 159-169
65. Vauthier C., Dubernet C., Chauvierre C., Brigger I., and Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release 93 (2003) 151-160
66. Miller D.W., Batrakova E.V., and Kabanov A.V. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm Res 16 (1999) 396-401
67. Mamot C., Drummond D.C., Hong K., Kirpotin D.B., and Park J.W. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Update 6 (2003) 271-279
68. Soma C.E., Dubernet C., Bentolila D., Benita S., and Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21 (2000) 1-7
69. Bangham A.D., Standish M.M., and Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13 (1965) 238-252
70. New R.R.C. Liposomes: a practical approach (1990), Oxford University Press, Oxford
71. Sethi V., Onyuksel H., and Rubinstein I. Liposomal vasoactive intestinal peptide. Methods Enzymol 391 (2005) 377-395
72. Devine D.V., Wong K., Serrano K., Chonn A., and Cullis P.R. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta 1191 (1994) 43-51
73. Pain D., Das P.K., Ghosh P.C., and Bachhawat B.K. Increased circulatory half-life of liposomes after conjugation with dextran. J Biosci 6 (1984) 811-816
74. Allen T.M., and Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 223 (1987) 42-46
75. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 88 (1991) 11460-11464
76. Lasic D.D., Martin F.J., Gabizon A., Huang S.K., and Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070 (1991) 187-192
77. Torchilin V.P., Levchenko T.S., Whiteman K.R., Yaroslavov A.A., Tsatsakis A.M., Rizos A.K., et al. Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification. Biomaterials 22 (2001) 3035-3044
78. Takeuchi H., Kojima H., Yamamoto H., and Kawashima Y. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Control Release 75 (2001) 83-91
79. Sejourne F., Suzuki H., Alkan-Onyuksel H., Gao X.P., Ikezaki H., and Rubinstein I. Mechanisms of vasodilation elicited by VIP in sterically stabilized liposomes in vivo. Am J Physiol 273 (1997) R287-R292
80. Sejourne F., Rubinstein I., Suzuki H., and Alkan-Onyuksel H. Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes. Pharm Res 14 (1997) 362-365
81. Onyuksel H., Ashok B., Dagar S., Sethi V., and Rubinstein I. Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity. Peptides 24 (2003) 281-286
82. Davidson R.N., Croft S.L., Scott A., Maini M., Moody A.H., and Bryceson A.D. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 337 (1991) 1061-1062
83. Guaglianone P., Chan K., DelaFlor-Weiss E., Hanisch R., Jeffers S., Sharma D., et al. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 12 (1994) 103-110
84. Gabizon A., Peretz T., Sulkes A., Amselem S., Ben-Yosef R., Ben-Baruch N., et al. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Cancer Clin Oncol 25 (1989) 1795-1803
85. Proulx M.E., Desormeaux A., Marquis J.F., Olivier M., and Bergeron M.G. Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother 45 (2001) 2623-2627
86. Giles F.J., Tallman M.S., Garcia-Manero G., Cortes J.E., Thomas D.A., Wierda W.G., et al. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 100 (2004) 1449-1458
87. Verschraegen C.F., Gilbert B.E., Loyer E., Huaringa A., Walsh G., Newman R.A., et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 10 (2004) 2319-2326
88. Zamboni W.C., Gervais A.C., Egorin M.J., Schellens J.H., Zuhowski E.G., Pluim D., et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 53 (2004) 329-336
89. Donald P.R., Sirgel F.A., Venter A., Smit E., Parkin D.P., VandeWal B.W., et al. The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis. J Antimicrob Chemother 48 (2001) 877-880
90. Kadry A.A., Al-Suwayeh S.A., Abd-Allah A.R., and Bayomi M.A. Treatment of experimental osteomyelitis by liposomal antibiotics. J Antimicrob Chemother 54 (2004) 1103-1108
91. Rudin C.M., Marshall J.L., Huang C.H., Kindler H.L., Zhang C., Kumar D., et al. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 10 (2004) 7244-7251
92. Chien P.Y., Wang J., Carbonaro D., Lei S., Miller B., Sheikh S., et al. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther 12 (2004) 321-328
93. Asano T., and Kleinerman E.S. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother 14 (1993) 286-292
94. Dagar S., Krishnadas A., Rubinstein I., Blend M.J., and Onyuksel H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J Control Release 91 (2003) 123-133
95. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8 (2002) 1172-1181
96. Pakunlu R.I., Wang Y., Tsao W., Pozharov V., Cook T.J., and Minko T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res 64 (2004) 6214-6224
97. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Shmeeda H., and Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 9 (2003) 6551-6559
98. Tanford C. The hydrophobic effect: formation of micelles and biological membranes. 2nd ed. (1991), Kreiger Publishing Company, Malabar (Fla)
99. Kwon G.S. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst 20 (2003) 357-403
100. Torchilin V.P. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv Drug Deliv Rev 54 (2002) 235-252
101. Ashok B., Arleth L., Hjelm R.P., Rubinstein I., and Onyuksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J Pharm Sci 93 (2004) 2476-2487
102. LeGarrec D., Ranger M., and Leroux J.C. Micelles in anticancer drug delivery. Am J Drug Deliv 2 (2004) 15-42
103. Lukyanov A.N., Gao Z., Mazzola L., and Torchilin V.P. Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res 19 (2002) 1424-1429
104. Working P.K., and Dayan A.D. Pharmacological-toxicological expert report. CAELYX (Stealth liposomal doxorubicin HCl). Hum Exp Toxicol 15 (1996) 751-785
105. Wade A., and Weller P.J. Handbook of pharmaceutical excipients (1994), American Pharmaceutical Association and Pharmaceutical Press, Washington (DC)
106. Onyuksel H., Ikezaki H., Patel M., Gao X.P., and Rubinstein I. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm Res 16 (1999) 155-160
107. Rabinow B.E. Nanosuspensions in drug delivery. Nat Rev Drug Discov 3 (2004) 785-796
108. Arleth L., Ashok B., Onyuksel H., Thiyagarajan P., Jacob J., and Hjelm R.P. Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media. Langmuir 21 (2005) 3279-3290
109. Torchilin V.P., Lukyanov A.N., Gao Z., and Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A 100 (2003) 6039-6044
110. Torchilin V.P. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci 61 (2004) 2549-2559
111. Krishnadas A., Rubinstein I., Sekosan M., and Onyuksel H. Targeted delivery of paclitaxel to breast cancer by vasoactive intestinal peptide conjugated sterically stabilized phospholipid mixed micelles. AAPS J 6 Suppl 1 (2004) M1191
112. Johnston T.P., and Miller S.C. Toxicological evaluation of poloxamer vehicles for intramuscular use. Bull Parenteral Drug Assoc 39 (1985) 83-89
113. Kabanov A.V., Batrakova E.V., and Alakhov V.Y. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 82 (2002) 189-212
114. Cavallaro G., Maniscalco L., Licciardi M., and Giammona G. Tamoxifen-loaded polymeric micelles: preparation, physico-chemical characterization and in vitro evaluation studies. Macromol Biosci 4 (2004) 1028-1038
115. LeGarrec D., Gori S., Luo L., Lessard D., Smith D.C., Yessine M.A., et al. Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J Control Release 99 (2004) 83-101
116. Batrakova E.V., Li S., Alakhov V.Y., Elmquist W.F., Miller D.W., and Kabanov A.V. Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm Res 20 (2003) 1581-1590
117. Kabanov A.V., Batrakova E.V., and Alakhov V.Y. An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers. J Control Release 91 (2003) 75-83
118. Batrakova E.V., Li S., Alakhov V.Y., Miller D.W., and Kabanov A.V. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther 304 (2003) 845-854
119. Kabanov A.V., Batrakova E.V., and Alakhov V.Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 54 (2002) 759-779
120. Danson S., Ferry D., Alakhov V., Margison J., Kerr D., Jowle D., et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 90 (2004) 2085-2091
121. Barreiro-Iglesias R., Bromberg L., Temchenko M., Hatton T.A., and Concheiro A. Solubilization and stabilization of camptothecin in micellar solutions of pluronic-g-poly(acrylic acid) copolymers. J Control Release 97 (2004) 537-549
122. Rapoport N., Pitt W.G., Sun H., and Nelson J.L. Drug delivery in polymeric micelles: from in vitro to in vivo. J Control Release 91 (2003) 85-95
123. Husseini G.A., Runyan C.M., and Pitt W.G. Investigating the mechanism of acoustically activated uptake of drugs from Pluronic micelles. BMC Cancer 2 (2002) 20
124. Pruitt J.D., and Pitt W.G. Sequestration and ultrasound-induced release of doxorubicin from stabilized Pluronic P105 micelles. Drug Deliv 9 (2002) 253-258
125. Ojugo A.S., McSheehy P.M., McIntyre D.J., McCoy C., Stubbs M., Leach M.O., et al. Measurement of the extracellular pH of solid tumours in mice by magnetic resonance spectroscopy: a comparison of exogenous (19)F and (31)P probes. NMR Biomed 12 (1999) 495-504
126. Lee E.S., Na K., and Bae Y.H. Polymeric micelle for tumor pH and folate-mediated targeting. J Control Release 91 (2003) 103-113
127. Engin K., Leeper D.B., Cater J.R., Thistlethwaite A.J., Tupchong L., and McFarlane J.D. Extracellular pH distribution in human tumours. Int J Hyperthermia 11 (1995) 211-216
128. Lee E.S., Na K., and Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 103 (2005) 405-418
129. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91 (2004) 1775-1781
130. Kakizawa Y., Harada A., and Kataoka K. Glutathione-sensitive stabilization of block copolymer micelles composed of antisense DNA and thiolated poly(ethylene glycol)-block-poly(L-lysine): a potential carrier for systemic delivery of antisense DNA. Biomacromolecules 2 (2001) 491-497
131. Lavasanifar A., Samuel J., and Kwon G.S. Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Adv Drug Deliv Rev 54 (2002) 169-190
132. Li Y., and Kwon G.S. Methotrexate esters of poly(ethylene oxide)-block-poly(2-hydroxyethyl-L-aspartamide). Part I: effects of the level of methotrexate conjugation on the stability of micelles and on drug release. Pharm Res 17 (2000) 607-611
133. Bae Y., Nishiyama N., Fukushima S., Koyama H., Yasuhiro M., and Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem 16 (2005) 122-130
134. Lin W.J., Juang L.W., and Lin C.C. Stability and release performance of a series of pegylated copolymeric micelles. Pharm Res 20 (2003) 668-673
135. Kim S.C., Kim D.W., Shim Y.H., Bang J.S., Oh H.S., Wan Kim S., et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 72 (2001) 191-202
136. Shuai X., Ai H., Nasongkla N., Kim S., and Gao J. Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J Control Release 98 (2004) 415-426
137. Yoo H.S., and Park T.G. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 96 (2004) 273-283
138. Podlogar F., Gasperlin M., Tomsic M., Jamnik A., and Rogac M.B. Structural characterisation of water-Tween 40/Imwitor 308-isopropyl myristate microemulsions using different experimental methods. Int J Pharm 276 (2004) 115-128
139. Brime B., Frutos P., Bringas P., Nieto A., Ballesteros M.P., and Frutos G. Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models. J Antimicrob Chemother 52 (2003) 103-109
140. He L., Wang G.L., and Zhang Q. An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. Int J Pharm 250 (2003) 45-50
141. Seki J., Sonoke S., Saheki A., Fukui H., Sasaki H., and Mayumi T. A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting. Int J Pharm 273 (2004) 75-83
142. Santos-Magalhaes N.S., Pontes A., Pereira V.M., and Caetano M.N. Colloidal carriers for benzathine penicillin G: nanoemulsions and nanocapsules. Int J Pharm 208 (2000) 71-80
143. Tadros T., Izquierdo P., Esquena J., and Solans C. Formation and stability of nano-emulsions. Adv Colloid Interface Sci 108-109 (2004) 303-318
144. Junping W., Takayama K., Nagai T., and Maitani Y. Pharmacokinetics and antitumor effects of vincristine carried by microemulsions composed of PEG-lipid, oleic acid, vitamin E and cholesterol. Int J Pharm 251 (2003) 13-21
145. Kang B.K., Chon S.K., Kim S.H., Jeong S.Y., Kim M.S., Cho S.H., et al. Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. Int J Pharm 286 (2004) 147-156
146. Fukui H., Koike T., Saheki A., Sonoke S., and Seki J. A novel delivery system for amphotericin B with lipid nano-sphere (LNS). Int J Pharm 265 (2003) 37-45
147. Kayser O., Olbrich C., Yardley V., Kiderlen A.F., and Croft S.L. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 254 (2003) 73-75
148. Muller R.H., and Keck C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 113 (2004) 151-170
149. Lee J., Lee S.J., Choi J.Y., Yoo J.Y., and Ahn C.H. Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur J Pharm Sci 24 (2005) 441-449
150. Merisko-Liversidge E., Sarpotdar P., Bruno J., Hajj S., Wei L., Peltier N., et al. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 13 (1996) 272-278
151. Thote A.J., and Gupta R.B. Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release. Nanomedicine 1 (2005) 85-90
152. Gessner A., Waicz R., Lieske A., Paulke B., Mader K., and Muller R.H. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm 196 (2000) 245-249
153. Zweers M.L., Engbers G.H., Grijpma D.W., and Feijen J. In vitro degradation of nanoparticles prepared from polymers based on dl-lactide, glycolide and poly(ethylene oxide). J Control Release 100 (2004) 347-356
154. Leo E., Brina B., Forni F., and Vandelli M.A. In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. Int J Pharm 278 (2004) 133-141
155. Sinha V.R., Bansal K., Kaushik R., Kumria R., and Trehan A. Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int J Pharm 278 (2004) 1-23
156. Csaba N., Gonzalez L., Sanchez A., and Alonso M.J. Design and characterisation of new nanoparticulate polymer blends for drug delivery. J Biomater Sci Polym Ed 15 (2004) 1137-1151
157. Birnbaum D.T., and Brannon-Peppas L. Molecular weight distribution changes during degradation and release of PLGA nanoparticles containing epirubicin HCl. J Biomater Sci Polym Ed 14 (2003) 87-102
158. Panyam J., Williams D., Dash A., Leslie-Pelecky D., and Labhasetwar V. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci 93 (2004) 1804-1814
159. Shenoy D.B., and Amiji M.M. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm 293 (2005) 261-270
160. Molpeceres J., Chacon M., Guzman M., Berges L., and del Rosario Aberturas M. A polycaprolactone nanoparticle formulation of cyclosporin-A improves the prediction of area under the curve using a limited sampling strategy. Int J Pharm 187 (1999) 101-113
161. Radwan M.A., Zaghloul I.Y., and Aly Z.H. In vivo performance of parenteral theophylline-loaded polyisobutylcyanoacrylate nanoparticles in rats. Eur J Pharm Sci 8 (1999) 95-98
162. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21 (2000) 2475-2490
163. Mainardes R.M., and Silva L.P. Drug delivery systems: past, present, and future. Curr Drug Targets 5 (2004) 449-455
164. Galindo-Rodriguez S., Allemann E., Fessi H., and Doelker E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res 21 (2004) 1428-1439
165. Leobandung W., Ichikawa H., Fukumori Y., and Peppas N.A. Preparation of stable insulin-loaded nanospheres of poly(ethylene glycol) macromers and N-isopropyl acrylamide. J Control Release 80 (2002) 357-363
166. Bharali D.J., Sahoo S.K., Mozumdar S., and Maitra A. Cross-linked polyvinylpyrrolidone nanoparticles: a potential carrier for hydrophilic drugs. J Colloid Interface Sci 258 (2003) 415-423
167. Zara G.P., Cavalli R., Bargoni A., Fundaro A., Vighetto D., and Gasco M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 10 (2002) 327-335
168. Yang S.C., Lu L.F., Cai Y., Zhu J.B., Liang B.W., and Yang C.Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 59 (1999) 299-307
169. Dingler A., and Gohla S. Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J Microencapsul 19 (2002) 11-16
170. Scholer N., Hahn H., Muller R.H., and Liesenfeld O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 231 (2002) 167-176
171. Roy I., Ohulchanskyy T.Y., Pudavar H.E., Bergey E.J., Oseroff A.R., Morgan J., et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc 125 (2003) 7860-7865
172. Gemeinhart R.A., Luo D., and Saltzman W.M. Cellular fate of a modular DNA delivery system mediated by silica nanoparticles. Biotechnol Prog 21 (2005) 532-537
173. Zhang L., Hou S., Mao S., Wei D., Song X., and Lu Y. Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. Int J Pharm 287 (2004) 155-162
174. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5 (2005) 161-171
175. Garber K. Improved Paclitaxel formulation hints at new chemotherapy approach. J Natl Cancer Inst 96 (2004) 90-91
176. Rhaese S., vonBriesen H., Rubsamen-Waigmann H., Kreuter J., and Langer K. Human serum albumin-polyethylenimine nanoparticles for gene delivery. J Control Release 92 (2003) 199-208
177. Wartlick H., Spankuch-Schmitt B., Strebhardt K., Kreuter J., and Langer K. Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles. J Control Release 96 (2004) 483-495
178. Vinogradov S.V., Batrakova E.V., and Kabanov A.V. Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem 15 (2004) 50-60
179. McAllister K., Sazani P., Adam M., Cho M.J., Rubinstein M., Samulski R.J., et al. Polymeric nanogels produced via inverse microemulsion polymerization as potential gene and antisense delivery agents. J Am Chem Soc 124 (2002) 15198-15207
180. Boas U., and Heegaard P.M. Dendrimers in drug research. Chem Soc Rev 33 (2004) 43-63
181. Quintana A., Raczka E., Piehler L., Lee I., Myc A., Majoros I., et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19 (2002) 1310-1316
182. Cloninger M.J. Biological applications of dendrimers. Curr Opin Chem Biol 6 (2002) 742-748
183. El-Sayed M., Kiani M.F., Naimark M.D., Hikal A.H., and Ghandehari H. Extravasation of poly(amidoamine) (PAMAM) dendrimers across microvascular network endothelium. Pharm Res 18 (2001) 23-28
184. Hawker C.J., and Frechet J.M.J. Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J Am Chem Soc 112 (1990) 7638-7647
185. Chauhan A.S., Jain N.K., Diwan P.V., and Khopade A.J. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J Drug Target 12 (2004) 575-583
186. Kim T.I., Seo H.J., Choi J.S., Jang H.S., Baek J.U., Kim K., et al. PAMAM-PEG-PAMAM: novel triblock copolymer as a biocompatible and efficient gene delivery carrier. Biomacromolecules 5 (2004) 2487-2492
187. Braun C.S., Vetro J.A., Tomalia D.A., Koe G.S., Koe J.G., and Russell Middaugh C. Structure/function relationships of polyamidoamine/DNA dendrimers as gene delivery vehicles. J Pharm Sci 94 (2004) 423-436
188. Manunta M., Tan P.H., Sagoo P., Kashefi K., and George A.J. Gene delivery by dendrimers operates via a cholesterol dependent pathway. Nucleic Acids Res 32 (2004) 2730-2739
189. Hollins A.J., Benboubetra M., Omidi Y., Zinselmeyer B.H., Schatzlein A.G., Uchegbu I.F., et al. Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor. Pharm Res 21 (2004) 458-466
190. Jevprasesphant R., Penny J., Jalal R., Attwood D., McKeown N.B., and D'Emanuele A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 252 (2003) 263-266
191. Nigavekar S.S., Sung L.Y., Llanes M., El-Jawahri A., Lawrence T.S., Becker C.W., et al. 3H dendrimer nanoparticle organ/tumor distribution. Pharm Res 21 (2004) 476-483
192. Tripathi P.K., Khopade A.J., Nagaich S., Shrivastava S., Jain S., and Jain N.K. Dendrimer grafts for delivery of 5-fluorouracil. Pharmazie 57 (2002) 261-264
193. Hussain M., Shchepinov M., Sohail M., Benter I.F., Hollins A.J., Southern E.M., et al. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. J Control Release 99 (2004) 139-155
194. Reubi J.C. In vitro identification of VIP receptors in human tumors: potential clinical implications. Ann N Y Acad Sci 805 (1996) 753-759
195. Reubi J.C. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 36 (1995) 1846-1853
196. Bertini I., Bianchini F., Calorini L., Colagrande S., Fragai M., Franchi A., et al. Persistent contrast enhancement by sterically stabilized paramagnetic liposomes in murine melanoma. Magn Reson Med 52 (2004) 669-672
197. Dagar S., Rubinstein I., and Onyuksel H. Liposomes in ultrasound and gamma scintigraphic imaging. Methods Enzymol 373 (2003) 198-214
198. Oku N., Tokudome Y., Tsukada H., and Okada S. Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography. Biochim Biophys Acta 1238 (1995) 86-90
199. Iyer M., Berenji M., Templeton N.S., and Gambhir S.S. Noninvasive imaging of cationic lipid-mediated delivery of optical and PET reporter genes in living mice. Mol Ther 6 (2002) 555-562
200. Sahoo S.K., and Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 8 (2003) 1112-1120
201. Voura E.B., Jaiswal J.K., Mattoussi H., and Simon S.M. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med 10 (2004) 993-998
202. Akerman M.E., Chan W.C., Laakkonen P., Bhatia S.N., and Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 99 (2002) 12617-12621
203. Dubertret B., Skourides P., Norris D.J., Noireaux V., Brivanlou A.H., and Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 298 (2002) 1759-1762
204. Wang W., and Asher S.A. Photochemical incorporation of silver quantum dots in monodisperse silica colloids for photonic crystal applications. J Am Chem Soc 123 (2001) 12528-12535
205. Vu T.Q., Maddipati R., Blute T.A., Nehilla B.J., Nusblat L., and Desai T.A. Peptide-conjugated quantum dots activate neuronal receptors and initiate downstream signaling of neurite growth. Nano Lett 5 (2005) 603-607
206. Gandon Y., Heautot J.F., Brunet F., Guyader D., Deugnier Y., and Carsin M. Superparamagnetic iron oxide: clinical time-response study. Eur J Radiol 12 (1991) 195-200
207. Gupta A.K., Berry C., Gupta M., and Curtis A. Receptor-mediated targeting of magnetic nanoparticles using insulin as a surface ligand to prevent endocytosis. IEEE Trans Nanobioscience 2 (2003) 255-261
208. Moffat B.A., Reddy G.R., McConville P., Hall D.E., Chenevert T.L., Kopelman R.R., et al. A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging 2 (2003) 324-332
209. Peira E., Marzola P., Podio V., Aime S., Sbarbati A., and Gasco M.R. In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide. J Drug Target 11 (2003) 19-24
210. Kobayashi H., Kawamoto S., Jo S.K., BryantJr H.L., Brechbiel M.W., and Star R.A. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem 14 (2003) 388-394
211. Kobayashi H., and Brechbiel M.W. Dendrimer-based nanosized MRI contrast agents. Curr Pharm Biotechnol 5 (2004) 539-549
212. Wang S.J., Brechbiel M., and Wiener E.C. Characteristics of a new MRI contrast agent prepared from polypropyleneimine dendrimers, generation 2. Invest Radiol 38 (2003) 662-668